New oral cancer drug enters first human trials
NCT ID NCT06258408
Summary
This is the first study in humans to test an oral tablet called BB102 for patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also check for early signs that the drug might help control tumor growth in certain cancers, particularly liver cancer with specific genetic markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Email: •••••@•••••
-
Nanfang Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.